All News

The Safety Review Committee has recommended that the trial proceed with the cohort expansion phase with no modifications to the protocol.

The next step is to prospectively validate the model in real-world clinical settings or within ongoing clinical trials.

Image-guided radiotherapy with reduced target margins may improve some dosimetric parameters and patient-reported urinary symptoms.

The ARTISAN trial includes both 177Lu-PSMA naïve and 177Lu-PSMA experienced cohorts.

The phase 2 study is looking to evaluate nadofaragene firadenovec in combination with the investigational light-activated small molecule TLD-1433 (Ruvidar).

Treatment failure occurred in 46% of patients in the high-risk group vs 21% of patients in the low-risk group.

The study is intended to support potential label expansion of testosterone undecanoate in men aged 65 to 80 years with hypogonadism.

Enolen is currently under investigation in a phase 1 trial to assess its safety and efficacy in delivering enzalutamide locally into the prostate.

The phase 2 PROHEAR trial is assessing the safety and efficacy of ACOU085 in preventing ototoxic hearing loss induced by cisplatin-based chemotherapy.

2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.

This episode delivers an empowering, forward-looking conversation on how APPs and physicians alike can lead health care transformation.

The study is being conducted as part of the landmark ProtecT trial.

Heidegger emphasizes that sexual concerns are almost never purely biological or purely psychological—they are biopsychosocial.

The code, J9282, went into effect on January 1, 2026.

According to the authors, these findings support the early use of genomic testing to guide treatment decisions.

"Although social media may not be for every health care worker, I hope that moving forward, more medical content creators will collaborate with the academic medical community to shape the world for the better," writes Maheetha Bharadwaj, MD.

A recap of the FDA submissions and regulatory decisions in urology from December 2025.

In this episode, Jeremy Y.C. Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery), joins host Adam Weiner, MD, to discuss en bloc vs standard transurethral resection of bladder tumor in NMIBC.

As the year comes to a close, we revisit some of this year’s top content in female urology.

As the year comes to a close, we revisit some of this year’s top content in men's health.

As the year comes to a close, we revisit some of this year’s top content on bladder cancer.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.

As the year comes to a close, we revisit some of this year’s top content on genomic testing.

As the year comes to a close, we revisit some of the top Urology Times podcast episodes from 2025.

Joshua Palka, DO, reflects on the key trends that shaped urologic oncology in 2025, emphasizing the growing role of precision medicine across disease states.

As the year comes to a close, we revisit some of this year’s top content on urology coding and reimbursement.